Xcovery is a biopharmaceutical company working to improve the lives of patients with cancer by discovering medicines to fight advanced tumors.  Xcovery is developing a pipeline of oncology therapies to target a wide range of advanced tumors.

Xcovery’s lead product, X-396, is a small molecule that inhibits anaplastic lymphoma kinase (ALK). X-396 is being investigated for the treatment of ALK positive non-small cell lung cancer. The Company is currently enrolling patients in its Phase 2 and Phase 3 human clinical trials.

Xcovery is also developing MET and PI3K/mTOR kinase inhibitors for advanced tumors..